|
23 June, 2026
|
ICON Reports First Quarter 2026 Results
|
|
|
22 June, 2026
|
ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development
|
|
|
17 June, 2026
|
ICON Schedules First Quarter 2026 Earnings Conference Call
|
|
|
27 May, 2026
|
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
|
|
|
26 May, 2026
|
ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq
|
|
|
13 May, 2026
|
ICON expands US early phase research capabilities with new clinic and outpatient centres
|
|
|
29 April, 2026
|
ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results
|
|
|
24 March, 2026
|
ICON and Advarra Introduce New ‘Research-Ready,’ Connected Site Network Model
|
|
|
12 February, 2026
|
ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices
|
|
|
27 January, 2026
|
ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership
|
|
|
09 December, 2025
|
ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive
|
|
|
02 December, 2025
|
ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions
|
|
|
12 November, 2025
|
ICON plc to Present at the Jefferies London Healthcare Conference
|
|
|
22 October, 2025
|
ICON Reports Third Quarter 2025 Results
|
|
|
24 September, 2025
|
ICON plc Schedules Third Quarter 2025 Earnings Conference Call
|
|
|
04 September, 2025
|
ICON Announces CEO Transition
|
|
|
02 September, 2025
|
ICON plc to Participate at Upcoming Investor Conferences
|
|
|
23 July, 2025
|
ICON Announces Results of Annual General Meeting
|
|
|
23 July, 2025
|
ICON Reports Second Quarter 2025 Results
|
|
|
16 July, 2025
|
ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
|
|
